PATENT CLAIM ANALYSIS

Application Number: 15753642
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "133100"]

Abstract:
Subject matter of the present invention is an Antibody or antibody fragment or non-Ig scaffold binding to a binding region of an anti-NMDAR1 antibody and its uses in therapy or diagnosis.

Claim (Index 1):
Antibody or antibody fragment or non-Ig scaffold binding specifically to a binding region of an anti-NMDAR1 antibody wherein the binding region of said anti-NMDAR1 antibody is comprised in one ore more sequences wherein said one or more sequence is selected from a group consisting of the following sequences: (003-109-HC) SEQ\u2003ID\u2003NO:\u20031 VQLVESGGGVVQPGRSLRLSCAAS GFTFSSYG MHWVRQAPGKGLEWVAV   IWYDGSNK YYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYC ARR   HYDFDAFDI WGQGTMVTVSS   (003-109-LC) SEQ\u2003ID\u2003NO:\u20032 QSALTQPASVSGSPGQSITISCTGT SSDVGGYNY VSWYQQHPGKAPKLM   IY EVS NRPSGVSNRFSGSKSGNTASLTISGLQAEDEADYYC SSYTSSST   LYV FGTGTKVTVL   (003-102-HC) SEQ\u2003ID\u2003NO:\u20033 QVQLQESGPGLVKPSGTLSLTCAVS GGSISSSNW WSWVRQPPGKGLEWI   GE IYHSGNT NYNPSLKSRVTVSVDKSKNQFSLKLTSVTAADTAVYYC AR   DVSGGVNWFDP WGQGTLVTVSS   (003-102-LC) SEQ\u2003ID\u2003NO:\u20034 NFMLTQPHSVSESPGKTVTISCTRS SGSIASNY VQWYQQRPGSAPTTVI   Y EDN QRPSGVPDRFSGSIDSSSNSASLTISGLKTEDEADYYC QSYDSST   VV FGGGTKLTVL   (007-168-HC) SEQ\u2003ID\u2003NO:\u20035 VQLVQSGAEAKKPGESLKISCKAS GYSFTTFW IGWVRQMPGSGLEWIGI   IYPGDSDT RYSPSFQGHVTISADRSTSTAYLQWSSLKASDTAMYYC ARS   AVFDY WGQGTLVTVSS   (007-168-LC) SEQ\u2003ID\u2003NO:\u20036 EIVMTQSPATLSVSPGGRATLSCRAS QSVSSN LAWYQQKPGQAPRLLIY   GAS TRATGIPVRFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPTSW   TFGQGTKVEIK   (007-169-HC) SEQ\u2003ID\u2003NO:\u20037 EVQLVQSGAEVKKPGESLKISCKGS GYSFTSYW IGWVRQMPGKGLEWMG   I IYPGDSD TRYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYC AR   DYGDYYFDY WGQGTLVTVSS   (007-169-LC) SEQ\u2003ID\u2003NO:\u20038 QSALTQPRSVSGSPGQSVTISCTGT SSDVGGYNY VSWYQQHPGKAPKLM   IY DVS KRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYC CSYAGSYT   GV FGEGTKLTVL   (007-124-HC) SEQ\u2003ID\u2003NO:\u20039 EVQLVESGGGVGRPGGSLRLSCAAS GFTFDDYG MSWVRQVPGKGLEWVS   G INWSGADT GYADSVKGRFTISRDNAKNSLYLQMNSLRVEDTALYHC AR   EVGIAVTGYWFDP WGQGTLVTV   (007-124-LC) SEQ\u2003ID\u2003NO:\u200310 SYELTQPPSVSVAPGQTARISCGGN HSES VHWYQQKPGQAPVLVVY DDS   DRPSGIPERFSGSKSGNTATLTISRVEGGDEAEYYC QVWDSSSDHPGVV   FGGGTKLTVL   (007-142-HC) SEQ\u2003ID\u2003NO:\u200311 EVQLVQSGAEVKKPGESLKISCKGS GYSFTSYW IGWVRQMPGKGLEWMG   I IYPGDSDT RYSPSFQGQVTISADKSISTAYLQWSSLKASDTAMYYC AR   DYGDYYFDY WGQGTLVTVSS   (007-142-LC) SEQ\u2003ID\u2003NO:\u200312 LTQPRSVSGSPGQSVTISCTGT SSDVGGYNY VSWYQQHPGKAPKLMIY D   VS KRPSGVPDRFSGSKSGNTASLTISGLQAEDEADYYC CSYAGSYTGV F   GGGTKLTVL   (008-218-HC) SEQ\u2003ID\u2003NO:\u200313 EVQLVESGGGLVQPGRSLRLSCAAS GFTFDDYA MHWVRQVPGKGLEWVS   G ISWSSGSI GYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTALYYC AK   DRASSWYAYGMDV WGQGTLVTV   (008-218-LC) SEQ\u2003ID\u2003NO:\u200314 NFMLTQPHSVSESPGKTVTISCTRS SGSIASNY VQWYQQRPGSSPTTVI   Y DDN QRPSGVPNRFSGSIDSSSNSASLIISGLKTEDEADYYC QSTRV FG   GGTKLTVL and wherein said binding region for the antibody or antibody fragment or non-Ig scaffold comprises or consists of one or several of the below mentioned sequences: SEQ\u2003ID\u2003NO:\u200315 GFTFSSYG   SEQ\u2003ID\u2003NO:\u200316 IWYDGSNK   SEQ\u2003ID\u2003NO:\u200317 ARRHYDFDAFDI   SEQ\u2003ID\u2003NO:\u200318 SSDVGGYNY   SEQ\u2003ID\u2003NO:\u200319 EVS   SEQ\u2003ID\u2003NO:\u200320 SSYTSSSTLYV   SEQ\u2003ID\u2003NO:\u200321 GGSISSSNW   SEQ\u2003ID\u2003NO:\u200322 IYHSGNT   SEQ\u2003ID\u2003NO:\u200323 ARDVSGGVNWFDP   SEQ\u2003ID\u2003NO:\u200324 SGSIASNY   SEQ\u2003ID\u2003NO:\u200325 EDN   SEQ\u2003ID\u2003NO:\u200326 QSYDSSTVV   SEQ\u2003ID\u2003NO:\u200327 GYSFTTFW   SEQ\u2003ID\u2003NO:\u200328 IYPGDSDT   SEQ\u2003ID\u2003NO:\u200329 ARSAVFDY   SEQ\u2003ID\u2003NO:\u200330 QSVSSN   SEQ\u2003ID\u2003NO:\u200331 GAS   SEQ\u2003ID\u2003NO:\u200332 QQYNNWPTSWT   SEQ\u2003ID\u2003NO:\u200333 GYSFTSYW   SEQ\u2003ID\u2003NO:\u200334 IYPGDSD   SEQ\u2003ID\u2003NO:\u200335 ARDYGDYYFDY   SEQ\u2003ID\u2003NO:\u200336 SSDVGGYNY   SEQ\u2003ID\u2003NO:\u200337 DVS   SEQ\u2003ID\u2003NO:\u200338 CSYAGSYTGV   SEQ\u2003ID\u2003NO:\u200339 GFTFDDYG   SEQ\u2003ID\u2003NO:\u200340 INWSGADT   SEQ\u2003ID\u2003NO:\u200341 AREVGIAVTGYWFDP   SEQ\u2003ID\u2003NO:\u200342 HSES   SEQ\u2003ID\u2003NO:\u200343 DDS   SEQ\u2003ID\u2003NO:\u200344 QVWDSSSDHPGVV   SEQ\u2003ID\u2003NO:\u200345 GYSFTSYW   SEQ\u2003ID\u2003NO:\u200346 IYPGDSDT   SEQ\u2003ID\u2003NO:\u200347 ARDYGDYYFDY   SEQ\u2003ID\u2003NO:\u200348 SSDVGGYNY   SEQ\u2003ID\u2003NO:\u200349 DVS   SEQ\u2003ID\u2003NO:\u200350 CSYAGSYTGV   SEQ\u2003ID\u2003NO:\u200351 GFTFDDYA   SEQ\u2003ID\u2003NO:\u200352 ISWSSGSI   SEQ\u2003ID\u2003NO:\u200353 AKDRASSWYAYGMDV   SEQ\u2003ID\u2003NO:\u200354 SGSIASNY   SEQ\u2003ID\u2003NO:\u200355 DDN   SEQ\u2003ID\u2003NO:\u200356 QSTRV

Metadata:
- Claim Count in Document: 1.0
- Percentile: 88.0
- Lexical Diversity: 1.23077
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['13679294', '13617498', '14432957', '11049536', '14360694']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7331707815975931
- 35 USC 102 Novelty (BERT): 0.5058979718792862
- Combined Prediction Score: 0.7104435006257624
- Mean Citation Score: 252.778928
- Max Citation Score: 254.92064
- Similarity Product: 185.6783270745468

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 0

Dataset: test